Efficacy and safety of Garenoxacin for the prevention in the patients with hematological malignancies after chemotherapy

Efficacy and safety of Garenoxacin for the prevention in the patients with hematological malignancies after chemotherapy - Garenoxacin for the prevention in hematological malignancies

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004979

Enrollment

Registered

2011-01-31

Start date

2011-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematological malignancies

Interventions

Garenoxacin for prevention

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Hematological malignancies 2)Neutropenia is expected to continue for one week or more 3)Written informed consent was obtained from each patient before enrollment in the study 4)Patient who was judged that prophylaxis is necessary

Exclusion criteria

Exclusion criteria: 1)GRNX is obviously ineffective to the pathogen. 2)Patients with a history of allergy/severe adverse effect to quinolone antibacterial agents or garenoxacin 3)Allergic diathesis 4)Pregnancy/lactation 5)Age of 15 years or younger 6)Patient was received systemic antibacterial therapy within 14 days 7)Patients who are regarded as inadequate

Design outcomes

Primary

Measure	Time frame
Frequencies of feblile neutropenia	—

Secondary

Measure	Time frame
Frequencies of adverse events	—

Countries

Japan

Contacts

Public ContactHisashi Tsurumi

Gifu University Hospital First Department of Internal Medicine

htsuru@gifu-u.aco.jp058-230-6000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026